Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy? - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?

IBTV speaks with industry leaders at ASGCT 2026 about new approaches to manufacturing, reimbursement, treatment delivery, and long-term value that could bring cell and gene therapies to more patients

  • September 11, 2026

  • 2 min

Share

Original Source(s)

Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?

  • September 11, 2026

Related Content

Correction: Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion

The Effectiveness of Digital Intervention on Psychological Resilience in Postoperative Breast Cancer Patients During Chemotherapy Intervals: Quasi-Experimental Study

Nasal obstruction may worsen OSA indicators

Increases in apnea-hypopnea events were greatest among patients with an elevated baseline index, while evidence supporting mouth taping remained preliminary.